U.S. markets open in 4 hours 46 minutes
  • S&P Futures

    3,430.00
    -2.25 (-0.07%)
     
  • Dow Futures

    28,160.00
    -22.00 (-0.08%)
     
  • Nasdaq Futures

    11,640.75
    -20.00 (-0.17%)
     
  • Russell 2000 Futures

    1,614.10
    -0.70 (-0.04%)
     
  • Crude Oil

    41.13
    -0.57 (-1.37%)
     
  • Gold

    1,922.00
    +6.60 (+0.34%)
     
  • Silver

    25.13
    +0.15 (+0.60%)
     
  • EUR/USD

    1.1864
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    30.20
    +1.02 (+3.50%)
     
  • GBP/USD

    1.3045
    +0.0099 (+0.76%)
     
  • USD/JPY

    104.9290
    -0.5410 (-0.51%)
     
  • BTC-USD

    12,168.47
    +1,111.46 (+10.05%)
     
  • CMC Crypto 200

    244.61
    +5.69 (+2.38%)
     
  • FTSE 100

    5,813.07
    -76.15 (-1.29%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

AstraZeneca Has Lost The Lead In Race For Coronavirus Vaccine, Says SVB Leerink

Shanthi Rexaline
·2 mins read

AstraZeneca plc's (NYSE: AZN) prospects at being the first mover in the competition to develop a coronavirus vaccine have dimmed, according to an analyst at SVB Leerink.

The AstraZeneca Analyst: Andrew Berens has an Outperform rating on AstraZeneca with a $65 price target.

The AstraZeneca Takeaways: The clinical trial hold on AstraZeneca's coronavirus vaccine candidate AZD1222, which remains in place other than in the U.K., and the relatively higher number of COVID-19 cases needed for an interim analysis suggest the British drug maker may have ceded the lead, Berens said in a Monday note.

This means AstraZeneca's vaccine candidate may not be the first to receive emergency use authorization, the analyst said. 

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The U.S. trial remains on hold after the company voluntarily stalled clinical trials across sites following a case of transverse myelitis, an adverse event, he said. 

An AstraZeneca clinical study protocol released over the weekend showed that an interim and primary efficacy endpoint estimate should be at least 50%, and that the lower bound of the confidence interval should be greater than 30%, Berens said. 

The first interim analysis will occur after 75 COVID-19 cases are reported, and the criteria for success will be statistical significance with an observed vaccine efficacy point estimate of at least 50%, the analyst said. 

The primary analysis will then follow after a total of 150 cases, with the criteria for success for the primary analysis being statistical significance with an observed vaccine efficacy point estimate of at least 50%, according to SVB Leerink. 

AstraZeneca Price Action: AstraZeneca shares were down 2.32% at $55.16 at last check Monday. 

Related Links:

The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix

Is AstraZeneca Still A Safe Bet?

Latest Ratings for AZN

Date

Firm

Action

From

To

May 2020

SVB Leerink

Maintains

Outperform

May 2020

Argus Research

Maintains

Buy

Dec 2019

Cowen & Co.

Maintains

Outperform

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.